AGM
MCRB icon

Alpine Global Management’s Seres Therapeutics MCRB Stock Holding History

Alpine Global Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-708
Closed -$67.9K – 208
2023
Q2 		$67.9K Buy
+708
New +$77K 0.02% 181
2022
Q1 		– Sell
-529
Closed -$88K – 604
2021
Q4 		$88K Buy
+529
New +$84.1K 0.01% 686

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Alpine Global Management's MCRB Position: Q3 2023 in Review

Alpine Global Management sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 708 shares — an estimated $67.9K sold.

Alpine Global Management first reported a position in MCRB in Q4 2021 and held it in 2 quarters. The position peaked at $88K in Q4 2021. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Alpine Global Management reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alpine Global Management sold 708 Seres Therapeutics shares in Q3 2023, an estimated $67.9K.
  • Alpine Global Management first reported a position in Seres Therapeutics in Q4 2021 and held it in 2 quarters.
  • Alpine Global Management's Seres Therapeutics position peaked at $88K in Q4 2021.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Alpine Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.